

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Hutchison Whampoa Limited

*(incorporated in Hong Kong with limited liability)*  
**(Stock Code: 13)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 70.9% owned subsidiary of Hutchison Whampoa Limited.

As at the date of this announcement, the Directors of the Company are:

**Executive Directors:**

Mr LI Ka-shing (*Chairman*)  
Mr LI Tzar Kuoi, Victor (*Deputy Chairman*)  
Mr FOK Kin-ning, Canning  
Mrs CHOW WOO Mo Fong, Susan  
Mr Frank John SIXT  
Mr LAI Kai Ming, Dominic  
Mr KAM Hing Lam

**Independent Non-executive Directors:**

The Hon Sir Michael David KADOORIE  
Mr Holger KLUGE  
Mrs Margaret LEUNG KO May Yee  
Mr William Elkin MOCATTA  
*(Alternate to The Hon Sir Michael David Kadoorie)*  
Mr WONG Chung Hin

**Non-executive Directors:**

Mr George Colin MAGNUS  
Mr William SHURNIAK

Hong Kong, 10 December 2010



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**China Healthcare Division  
Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture**

**London: Friday, 10 December 2010:** Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces the intended indirect increase in its ownership of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), one of the companies which comprise Chi-Med’s China Healthcare Division.

HBYS primarily engages in the manufacture and sale of over-the-counter traditional Chinese medicines. Chi-Med’s wholly-owned subsidiary, Hutchison Chinese Medicine Holding Limited, has entered into agreements with Bestchosen Limited (“Bestchosen”), Dian Son Development Limited and Hutchison BYS (Guangzhou) Holding Limited (“HGHL”), to increase its equity interest in HGHL from 75% to 80%, for a total cash consideration of approximately US\$2.7 million. HGHL currently indirectly holds 50% interest in HBYS.

Since its first full year in 2006, HGHL has recorded compound average annual sales growth of 25% as a result of growth in HBYS antiviral drug sales driven by the severe flu seasons in China in recent years. The sales and net profits of HGHL in 2009 were US\$67.8 million and \$7.4 million respectively.

Bestchosen was a 25% shareholder of HGHL and was a related party to Chi-Med under Rule 13 of the AIM Rules for Companies and accordingly, where the transactions with Bestchosen contemplated in one of the above agreements constituted related party transactions for the purposes of AIM Rule 13. Chi-Med’s directors consider, having consulted with Chi-Med’s nominated adviser that the terms of the transactions with Bestchosen are fair and reasonable insofar as Chi-Med’s shareholders are concerned.

**Ends**

**Enquiries**

**Chi-Med**  
Christian Hogg, CEO

Telephone: +852 2121 8200

**Citigate Dewe Rogerson**  
Anthony Carlisle  
David Dible

Telephone: +44 (0) 20 7638 9571  
Mobile: +44 (0) 7973 611 888  
Mobile: +44 (0) 7967 566 919

**Lazard & Co., Limited**  
Paul Gismondi  
Nick Fowler

Telephone: +44 (0) 20 7187 2000

## **About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.